Clinical Trial Update: Upadacitinib for Refractory Behcet's Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 study of upadacitinib for refractory Behçet's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Upadacitinib (upadacitinib)

Snippet

Sponsor: Liu Tian | Conditions: Behcet Syndrome | Phase 2 | Status: COMPLETED